Sun Wook Cho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5934039/publications.pdf

Version: 2024-02-01

76 papers

2,180 citations

236925 25 h-index 243625 44 g-index

80 all docs

80 docs citations

80 times ranked 3460 citing authors

#	Article	IF	CITATIONS
1	Abstract P5-05-08: CXCL16 as a potential therapeutic target of triple-negative breast cancer. Cancer Research, 2022, 82, P5-05-08-P5-05-08.	0.9	O
2	Active Surveillance Versus Immediate Surgery for Low-Risk Papillary Thyroid Microcarcinoma Patients in South Korea: A Cost-Minimization Analysis from the MAeSTro Study. Thyroid, 2022, 32, 648-656.	4.5	14
3	Evaluation and Management of Bone Health in Patients with Thyroid Diseases: a Position Statement from the Korean Thyroid Association. International Journal of Thyroidology, 2022, 15, 1-16.	0.1	4
4	Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves' Disease. Endocrinology and Metabolism, 2022, 37, 524-532.	3.0	3
5	A Cross-Sectional Survey of Patient Treatment Choice in a Multicenter Prospective Cohort Study on Active Surveillance of Papillary Thyroid Microcarcinoma (MAeSTro). Thyroid, 2022, 32, 772-780.	4.5	7
6	Metformin Reduces Thyroid Cancer Tumor Growth in the Metastatic Niche of Bone by Inhibiting Osteoblastic RANKL Productions. Thyroid, 2021, 31, 760-771.	4.5	12
7	Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 724-735.	3.6	23
8	Best Achievements in Translational and Basic Thyroidology in 2020. Endocrinology and Metabolism, 2021, 36, 36-40.	3.0	0
9	Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma. Endocrinology and Metabolism, 2021, 36, 359-364.	3.0	17
10	Secular Trends in Ablation Therapy for Graves' Disease: An Analysis of a 15-Year Experience at a Tertiary Hospital in South Korea. Journal of Clinical Medicine, 2021, 10, 1629.	2.4	2
11	Relationship Between lodine Status and Thyroid Function in Preschool Children: From the Environmental and Development of Children (EDC) Study. Journal of the Endocrine Society, 2021, 5, A720-A721.	0.2	O
12	Measurements of Bone Health after Thyroid-Stimulating Suppression Therapy in Postmenopausal Women with Differentiated Thyroid Carcinoma: Bone Mineral Density versus the Trabecular Bone Score. Journal of Clinical Medicine, 2021, 10, 1964.	2.4	6
13	Decreased Expression of Ileal Thyroid Hormone Transporters in a Hypothyroid Patient: A Case Report. Frontiers in Endocrinology, 2021, 12, 664839.	3.5	4
14	Comparison of Diagnostic Performance in Thyroid Nodules on US: Deep Convolutional Neural Network Models vs Endocrinologists With Various Experiences. Journal of the Endocrine Society, 2021, 5, A859-A859.	0.2	0
15	Increased expression of thyroid hormone receptor alpha and estrogen receptor alpha in breast cancer associated with thyroid cancer. European Journal of Surgical Oncology, 2021, 47, 1316-1323.	1.0	9
16	Clinicopathological Characteristics and Recurrence-Free Survival of Rare Variants of Papillary Thyroid Carcinomas in Korea: A Retrospective Study. Endocrinology and Metabolism, 2021, 36, 619-627.	3.0	6
17	A beneficial role of computer-aided diagnosis system for less experienced physicians in the diagnosis of thyroid nodule on ultrasound. Scientific Reports, 2021, 11, 20448.	3.3	8
18	Diagnosing thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology with the deep convolutional neural network. Scientific Reports, 2021, 11, 20048.	3.3	6

#	Article	IF	Citations
19	Comparison of Korean vs. American Thyroid Imaging Reporting and Data System in Malignancy Risk Assessment of Indeterminate Thyroid Nodules. Endocrinology and Metabolism, 2021, 36, 1111-1120.	3.0	8
20	10-Year Fracture Risk in Postmenopausal Women with Osteopenia and Osteoporosis in South Korea. Endocrinology and Metabolism, 2021, 36, 1178-1188.	3.0	12
21	Circulating Osteocalcinâ€Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients. Journal of Bone and Mineral Research, 2020, 35, 1838-1849.	2.8	15
22	Clinical factors predicting the successful discontinuation of hormone replacement therapy in patients diagnosed with primary hypothyroidism. PLoS ONE, 2020, 15, e0233596.	2.5	0
23	Multifaceted Actions of Succinate as a Signaling Transmitter Vary with Its Cellular Locations. Endocrinology and Metabolism, 2020, 35, 36.	3.0	24
24	A High Frequency of Lobectomy Instead of Total Thyroidectomy to Treat Medullary Thyroid Cancer in Korea: Data from the Korean National Health Insurance Service. Endocrinology and Metabolism, 2020, 35, 784-785.	3.0	3
25	A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive lodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol. Endocrinology and Metabolism. 2020. 35, 571-577.	3.0	0
26	Thyroid Metastasis from Breast and Lung Cancer in Patients with Underlying Hashimoto's Thyroiditis. International Journal of Thyroidology, 2020, 13, 175-180.	0.1	0
27	CXCL16 positively correlated with M2-macrophage infiltration, enhanced angiogenesis, and poor prognosis in thyroid cancer. Scientific Reports, 2019, 9, 13288.	3.3	46
28	Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nature Communications, 2019, 10, 2764.	12.8	166
29	Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of) Tj ETQq1 1 0.78	434. \$ rgBT	' Gwerlock 1
30	Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer. Endocrine Journal, 2019, 66, 597-604.	1.6	18
31	Parathyroid adenoma with prominent lymphocytic infiltrate having histological features highly suggestive of IgG4-related disease: a case report and literature review. Endocrine Journal, 2019, 66, 379-385.	1.6	2
32	Aberrant Thyroid-Stimulating Hormone Receptor Signaling Increases VEGF-A and CXCL8 Secretion of Thyroid Cancer Cells, Contributing to Angiogenesis and Tumor Growth. Clinical Cancer Research, 2019, 25, 414-425.	7.0	28
33	Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer. Endocrinology and Metabolism, 2019, 34, 150.	3.0	33
34	Clinical Characteristics of Subtypes of Follicular Variant Papillary Thyroid Carcinoma. Thyroid, 2018, 28, 311-318.	4.5	40
35	Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis. Cancer Letters, 2018, 414, 205-213.	7.2	53
36	Star-Shaped Intense Uptake of 131I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq. Endocrinology and Metabolism, 2018, 33, 228.	3.0	4

#	Article	IF	CITATIONS
37	Effects of Maternal Iodine Status during Pregnancy and Lactation on Maternal Thyroid Function and Offspring Growth and Development: A Prospective Study Protocol for the Ideal Breast Milk Cohort. Endocrinology and Metabolism, 2018, 33, 395.	3.0	2
38	Comprehensive Transcriptomic and Genomic Profiling of Subtypes of Follicular Variant of Papillary Thyroid Carcinoma. Thyroid, 2018, 28, 1468-1478.	4.5	21
39	Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea. Surgery, 2018, 164, 312-318.	1.9	6
40	Changes in Body Compositions and Basal Metabolic Rates during Treatment of Graves' Disease. International Journal of Endocrinology, 2018, 2018, 1-8.	1.5	12
41	Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro). Endocrinology and Metabolism, 2018, 33, 278.	3.0	35
42	Effects of Coexistent <i>BRAF^{V600E}</i> Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis. Thyroid, 2017, 27, 651-660.	4.5	122
43	The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study. Thyroid, 2017, 27, 491-496.	4.5	25
44	Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer. European Journal of Endocrinology, 2017, 177, 465-473.	3.7	26
45	Enhancement of Osteogenic Differentiation by Combination Treatment with 5-azacytidine and Thyroid-Stimulating Hormone in Human Osteoblast Cells. International Journal of Thyroidology, 2017, 10, 71.	0.1	1
46	Synchronous metastasis from double primary cancers in a single left supraclavicular lymph node. Korean Journal of Internal Medicine, 2017, 32, 1121-1122.	1.7	0
47	Macrophage Densities Correlated with CXC Chemokine Receptor 4 Expression and Related with Poor Survival in Anaplastic Thyroid Cancer. Endocrinology and Metabolism, 2016, 31, 469.	3.0	22
48	Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment. Endocrinology and Metabolism, 2016, 31, 485.	3.0	13
49	New Biological Markers of Bone Metabolism in Osteoporosis Treatment. Endocrinology and Metabolism, 2016, 31, 400.	3.0	0
50	Effects of Thyroid Stimulating Hormone on Bone Metabolism. International Journal of Thyroidology, 2016, 9, 127.	0.1	4
51	Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer, 2016, 122, 1370-1379.	4.1	147
52	Thyroid-stimulating hormone improves insulin sensitivity in skeletal muscle cells via cAMP/PKA/CREB pathway-dependent upregulation of insulin receptor substrate-1 expression. Molecular and Cellular Endocrinology, 2016, 436, 50-58.	3.2	22
53	CXCL16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma. Endocrine-Related Cancer, 2016, 23, 113-124.	3.1	44
54	The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative ¹³¹ I dose over 37 <scp>GB</scp> q. Clinical Endocrinology, 2015, 83, 117-123.	2.4	29

#	Article	IF	Citations
55	Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea. Journal of Bone Metabolism, 2015, 22, 167.	1.3	22
56	Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates. Journal of Pathology and Translational Medicine, 2015, 49, 318-324.	1.1	137
57	Role of Osteal Macrophages in Bone Metabolism. Journal of Pathology and Translational Medicine, 2015, 49, 102-104.	1.1	26
58	Secular trends in the prognostic factors for papillary thyroid cancer. European Journal of Endocrinology, 2014, 171, 667-675.	3.7	23
59	Therapeutic Potential of Dickkopf-1 in Wild-Type BRAF Papillary Thyroid Cancer via Regulation of β-Catenin/E-cadherin Signaling. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1641-E1649.	3.6	14
60	Osteal macrophages support physiologic skeletal remodeling and anabolic actions of parathyroid hormone in bone. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1545-1550.	7.1	167
61	The role of ultrasound findings in the management of thyroid nodules with atypia or follicular lesions of undetermined significance. Clinical Endocrinology, 2014, 80, 735-742.	2.4	74
62	In Vivo Deletion of CAR Resulted in High Bone Mass Phenotypes in Male Mice. Journal of Cellular Physiology, 2014, 229, 561-571.	4.1	8
63	Long-Term Prognosis of Differentiated Thyroid Cancer with Lung Metastasis in Korea and Its Prognostic Factors. Thyroid, 2014, 24, 277-286.	4.5	80
64	Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. Molecular and Cellular Endocrinology, 2014, 393, 24-29.	3.2	39
65	Effect of Seasonal Changes on the Transition Between Subclinical Hypothyroid and Euthyroid Status. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3420-3429.	3.6	54
66	Positive regulation of osteogenesis by bile acid through FXR. Journal of Bone and Mineral Research, 2013, 28, 2109-2121.	2.8	67
67	Dickkopf-1 inhibits thyroid cancer cell survival and migration through regulation of \hat{l}^2 -catenin/E-cadherin signaling. Molecular and Cellular Endocrinology, 2013, 366, 90-98.	3.2	30
68	Parathyroid Hormone–Related Protein Drives a CD11b+Gr1+ Cell–Mediated Positive Feedback Loop to Support Prostate Cancer Growth. Cancer Research, 2013, 73, 6574-6583.	0.9	52
69	The Expression of Tumor-Associated Macrophages in Papillary Thyroid Carcinoma. Endocrinology and Metabolism, 2013, 28, 192.	3.0	47
70	Letter: Natural Course of Cytologically Benign Thyroid Nodules: Observation of Ultrasonographic Changes (Endocrinol Metab 2013;28:110-8, Dong Jun Lim et al.). Endocrinology and Metabolism, 2013, 28, 241.	3.0	0
71	Interactions between Immune Cells and Tumor Cells. Journal of Korean Thyroid Association, 2013, 6, 96.	0.2	2
72	Parathyroid Hormone: A Dynamic Regulator of Bone, Immune, and Hematopoietic Cells., 2013,, 57-71.		O

Sun Wook Cho

#	Article	IF	CITATION
73	Monogenic Thyroid Disorder. Journal of Korean Thyroid Association, 2012, 5, 83.	0.2	0
74	Osteoblast-targeted overexpression of PPAR \hat{I}^3 inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice. Journal of Bone and Mineral Research, 2011, 26, 1939-1952.	2.8	46
75	Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clinical Endocrinology, 2010, 72, 648-653.	2.4	80
76	Wnt inhibitory factor (WIF)-1 inhibits osteoblastic differentiation in mouse embryonic mesenchymal cells. Bone, 2009, 44, 1069-1077.	2.9	50